Revolution Medicines (RVMD) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 EPS (earnings per share) of -$1.83, reflecting ongoing R&D (research and development) investments in the RAS(ON) oncology pipeline.
• Consensus revenue forecast stands at approximately $3.6 million, consistent with the company's clinical-stage status.
• Recent $2.0 billion capital raise via stock and convertible notes significantly bolsters the balance sheet.
• Positive Phase 2 data for daraxonrasib in pancreatic cancer announced in April, with Phase 3 dosing underway.
• Full-year 2026 GAAP operating expenses guided at $1.6-$1.7 billion to support expanded trials.
• Historical post-earnings stock moves have been volatile, averaging around 10-13% implied volatility.

Earnings Context and Why It Matters

Revolution Medicines, a clinical-stage oncology company targeting RAS-mutated cancers, approaches its Q1 2026 earnings amid heightened investor interest. The report, expected in early May for the quarter ended March 31, 2026, follows blockbuster Phase 2 results for lead candidate daraxonrasib and a landmark $2 billion financing. With shares surging over 90% year-to-date, this earnings will provide critical updates on pipeline advancement, cash deployment, and burn rate. For investors, it offers insights into execution risks in late-stage trials and financial sustainability in a competitive biotech landscape, where RAS inhibitors represent a potential multi-billion-dollar market.

Earnings Expectations

Wall Street anticipates a consensus EPS of -$1.83 for Q1 2026, wider than the Q4 2025 actual of -$1.86, which missed estimates of -$1.56. Revenue is projected at $3.57 million on average, aligning with milestone payments and minimal product sales typical for a pre-commercial biotech. Investors will scrutinize R&D expenses against the $1.6-$1.7 billion full-year guidance, cash position post-financing (likely exceeding $3 billion), and updates on key metrics like trial enrollment and manufacturing scale-up.

Historically, Revolution Medicines has missed EPS estimates, as seen in Q4 2025's 19% shortfall. The stock has shown mixed reactions, with a -1.5% move post-Q4 release, though options imply ~13% volatility this time.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across diverse portfolios. Explore it today to uncover hidden gems in biotech and beyond.

Market Reaction and Investor Sentiment

Sentiment heading into Q1 earnings is bullish, propelled by April's positive daraxonrasib data—showing a 60% reduction in death risk versus chemotherapy in pancreatic cancer—and the subsequent $2 billion raise. Shares have rallied sharply, up over 50% in the past month. However, risks include higher-than-expected cash burn or delays in Phase 3 RASolute 303 trial enrollment. Options pricing suggests elevated volatility, with investors positioning for pipeline commentary over financials.

Forward Outlook and Key Factors to Monitor

Following Q1 results, attention will shift to Revolution Medicines' reaffirmed 2026 guidance and pipeline catalysts. The company expects GAAP operating expenses of $1.6-$1.7 billion, funding expanded RAS(ON) inhibitor programs amid recent trial successes.

Key to watch: progress in the Phase 3 RASolute 303 trial for daraxonrasib in first-line metastatic pancreatic cancer, where dosing began in April. Enrollment completion could enable 2027 data readouts, pivotal for regulatory paths. Additional updates on other assets like RMC-6236 (pan-RAS inhibitor) and combination studies will signal diversification.

Cash runway, now extended well into 2029 post-financing, mitigates dilution concerns but merits scrutiny on quarterly burn. Broader factors include competitive dynamics in KRAS-targeted therapies and potential partnerships. Investors should track management commentary on manufacturing, regulatory milestones, and any revised timelines.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations